Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

  • Doug Jones and the ACA, Epic misses a White House meeting, and man caves for man-flu sufferers
  • CVS-Aetna deal may trigger merger mania, Johns Hopkins criticized for lack of asthma prevention, & Columbia sees free-ride future for all of its med students

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.

News

Aimmune Therapeutics, Inc., has announced that its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18% pre-market, Reuters reports. The positive trial data comes nearly four months after French drug developer DBV Technologies SA’s stick-on patch…
The FDA has approved an amantadine extended-release tablet (Osmolex ER, Osmotica Pharmaceutical) for the treatment of Parkinson’s disease and for the treatment of drug-induced extrapyramidal reactions in adults. Extrapyramidal symptoms are known side effects of many common medications. Osmolex ER…
A mass shooting at a Florida high school that left 17 people dead has reopened a debate in Congress about loosening long-standing restrictions on Centers for Disease Control and Prevention (CDC) research into gun violence, according to an article in The Hill. Democrats have frequently railed against…
Less than one week after it scored approval from the FDA for Glatopa (glatiramer acetate injection), a generic version of Teva’s multiple sclerosis drug Copaxone, Novartis may be looking to sell off its generics subsidiary Sandoz, BioSpace reports. Citing unnamed sources “familiar with the matter,”…
To keep rising health care costs in check, many health insurers have adopted a strategy known as “step therapy,” a policy requiring patients to try cheaper drugs first—and find them to be ineffective—before approving pricier medication. However, some health care experts contend the approach,…
The FDA has approved a new indication for durvalumab (Imfinzi, AstraZeneca)–– treating patients with unresectable stage III non–small–cell lung cancer (NSCLC) whose cancer has not progressed after treatment with chemoradiation. Durvalumab becomes the first treatment approved to reduce the risk…
Promising new findings in the treatment of plaque psoriasis, oral ulcers, and genital psoriasis have been reported at the 2018 American Academy of Dermatology Annual Meeting in San Diego. Risankizumab Outperforms Stelara More patients with plaque psoriasis treated with risankizumab (AbbVie/ Boehringer…
A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences to pay a record $2.54 billion because its hepatitis C drugs sofosbuvir (Sovaldi) and ledipasvir/sofosbuvir (Harvoni) infringed a patent held by rival Merck & Company, according to a Reuters report. The verdict had…